Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 333,985
  • Shares Outstanding, K 23,454
  • Annual Sales, $ 82,710 K
  • Annual Income, $ -102,240 K
  • 60-Month Beta 1.07
  • Price/Sales 4.11
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade URGN with:

Options Overview Details

View History
  • Implied Volatility 113.44% ( -1.71%)
  • Historical Volatility 83.33%
  • IV Percentile 80%
  • IV Rank 38.17%
  • IV High 224.57% on 07/26/23
  • IV Low 44.84% on 03/13/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 12
  • Volume Avg (30-Day) 151
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 4,319
  • Open Int (30-Day) 2,731

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.93
  • Number of Estimates 3
  • High Estimate -0.87
  • Low Estimate -0.99
  • Prior Year -1.30
  • Growth Rate Est. (year over year) +28.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.37 +14.53%
on 04/11/24
18.23 -22.28%
on 03/25/24
-0.33 (-2.29%)
since 03/18/24
3-Month
12.37 +14.53%
on 04/11/24
19.87 -28.70%
on 02/16/24
-0.10 (-0.72%)
since 01/18/24
52-Week
8.69 +63.03%
on 07/26/23
24.13 -41.29%
on 08/15/23
+4.64 (+48.66%)
since 04/18/23

Most Recent Stories

More News
Why Shares of UroGen Pharma Jumped Friday

The company released positive top-line results for two studies for a bladder cancer treatment.

URGN : 14.25 (+0.07%)
Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of 6.47% and 3.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

URGN : 14.25 (+0.07%)
LFCR : 6.24 (-4.44%)
Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 2.70% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ACET : 2.09 (-7.93%)
URGN : 14.25 (+0.07%)
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2023...

URGN : 14.25 (+0.07%)
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline

Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

URGN : 14.25 (+0.07%)
CYTK : 67.39 (-0.79%)
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis...

URGN : 14.25 (+0.07%)
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis...

URGN : 14.25 (+0.07%)
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate...

URGN : 14.25 (+0.07%)
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

URGN : 14.25 (+0.07%)
HUMA : 3.66 (+17.31%)
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for...

URGN : 14.25 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

3rd Resistance Point 15.23
2nd Resistance Point 14.95
1st Resistance Point 14.59
Last Price 14.25
1st Support Level 13.95
2nd Support Level 13.67
3rd Support Level 13.31

See More

52-Week High 24.13
Fibonacci 61.8% 18.23
Fibonacci 50% 16.41
Fibonacci 38.2% 14.59
Last Price 14.25
52-Week Low 8.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar